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ABSTRACT:  
Lung cancer is the leading cause of cancer-related mortality worldwide in both sexes, expected to 
account, in the near future, for more than 30% of all cancer-related deaths. Recently, improvements 
in the systemic therapy of non-small-cell lung cancer according to histology and tumor molecular 
characteristics led to a progressive prolongation of survival, more clinically meaningful in selected 
groups of patients with tumors harboring specific genomic alterations. As the search for 
individualized therapeutic approaches could represent one of the potential ways to improve survival 
expectancy of non-small-cell lung cancer patients with advanced disease stage, the aim of this 
review is to discuss how currently to select the best front-line therapeutic strategy. 
Lung cancer is the leading cause of cancer-related mortality worldwide in both sexes and accounts 
for 26 and 29% of all female and male cancer deaths, respectively [1]. Incidence rates in women 
started declining in the late 1990s, more than a decade after observing the same trend in men [2]. 
Probably, differences in lung cancer incidence patterns between men and women reflect historical 
differences in tobacco use. 
The overall 5-year survival rate for lung cancer is currently approximately 16% and this rate drops 
down to 4% for those patients diagnosed at advanced stages [1,3]. 
Owing to relevant epidemiological changes and recent advances regarding systemic therapy of non-
small-cell lung cancer (NSCLC) according to histology and molecular characteristics, this review 
summarizes how to currently choose the best strategy of treatment in front-line setting for patients 
presenting with advanced disease stage. 
 
Role of cytotoxic chemotherapy 
 
A meta-analysis spanning 25 years of clinical research established that platinum-based 
chemotherapy doublets are the backbone of treatment for advanced NSCLC. This approach 
guarantees a modest but statistically significant improvement in survival and quality of life [4,5]. In 
addition, there is evidence that cisplatin is more effective than carboplatin in terms of objective 
response rate (ORR; 30 vs 24%, respectively; p < 0.001), despite a less favorable toxicity profile 
[6]. 
Commonly used platinum doublets demonstrate comparable activity with differential toxicity 
profiles (Table 1) [7–9]. In one study, the combination of cisplatin plus docetaxel showed a higher 
ORR and a better overall survival (OS) in comparison with the other explored regimens [9]. 
A retrospective review and meta-analysis demonstrated that triplet combinations are associated with 
an increase in ORR but not in progression-free (PFS) and OS compared with doublets [10]. Overall 
these findings suggest that chemotherapy for all comers as front-line approach for advanced 
NSCLC had already reached a therapeutic plateau. 
Histology-driven chemotherapy 
Evidence generated from a better knowledge of tumor cell biology and the development of drugs 
targeting specific enzymatic pathways of the tumor cell, such as the folate pathway, have shown 
that histology may become one of relevant finding in the therapeutic decision-making process of 
NSCLC. 
In a large Phase III randomized trial, cisplatin plus pemetrexed was not inferior to cisplatin plus 
gemcitabine for all the tested clinical efficacy outcomes [11]. This study included a preplanned 
analysis for histology, and patients with nonsquamous NSCLC benefited more from the 
pemetrexed-based regimen in terms of OS (hazard ratio [HR]: 0.81; 95% CI: 0.7–0.94; p = 0.005), 
while PFS did not differ between the two groups. On the contrary, patients with squamous cell 
carcinoma showed a marginally significant superiority in OS (10.8 vs 9.4 months, respectively; HR: 
1.23; 95% CI: 1.00–1.51; p = 0.05) and PFS (5.5 vs 4.4 months, respectively; HR: 1.36; 95% CI: 
1.12–1.65; p < 0.05) for patients treated with cisplatin plus gemcitabine. Cisplatin plus pemetrexed 
resulted in a statistically significant inferior incidence of grade 3 and 4 neutropenia, anemia, 
thrombocytopenia, febrile neutropenia and alopecia (p ≤ 0.001), whereas drug-related grade 3 and 4 
nausea was higher (p = 0.004). 
The differential activity of pemetrexed in nonsquamous histology has been also supported by a 
retrospective analysis of a Phase III trial of single-agent pemetrexed versus docetaxel in the second-
line treatment of recurrent NSCLC [12] and, prospectively, in a Phase III maintenance study of 
single-agent pemetrexed [13]. The benefit of continuation maintenance pemetrexed in nonsquamous 
NSCLC has been further supported by another Phase III study for advanced nonsquamous NSCLC 
[14,15]. 
These results have been related to a different expression of thymidylate synthase (TS), one of the 
main enzymes of the folate pathway targeted by pemetrexed, in different histologic subtypes of 
NSCLC, which may justify the lower efficacy of pemetrexed in the squamous histology being TS 
higher in this histotype [16]. 
Based on these data, patients with adenocarcinoma are more likely to benefit from a pemetrexed-
based regimen, and in 2008, pemetrexed in combination with cisplatin was been granted as first-line 
treatment for patients with advanced NSCLC other than predominantly squamous cell histology. 
The predictive role of histology is a peculiar finding in most of the studies investigating pemetrexed 
in NSCLC, while in previous studies, histology was not associated with any prognostic or 
predictive value [7,8,17]. 
Role of biological agents 
• Monoclonal antibodies anti-VEGF: bevacizumab  
Clinical research efforts with targeted agents have endeavored to improve survival beyond that 
provided by cytotoxic chemotherapy. The randomized trial ECOG E4599 assessed the addition of 
bevacizumab, a monoclonal antibody targeting the VEGF and inhibiting its interaction with the 
VEGF receptors, to carboplatin plus paclitaxel in patients with metastatic nonsquamous NSCLC. 
The study showed a statistically significant improvement in median OS for the group of 
bevacizumab-treated patients [18]. Median PFS and ORR were also improved. Adenocarcinoma 
histology was associated with a greater OS benefit (14.2 vs 10.3 months, respectively). The 
administration of bevacizumab was well tolerated, even if an excess of severe bleeding episodes 
was reported in the bevacizumab arm (4.4 vs 0.7%, respectively; p < 0.001). 
Based on the outcome of this trial, in 2006, the US FDA rapidly granted approval for bevacizumab 
administered in combination with carboplatin plus paclitaxel for the initial treatment of patients 
with unresectable, locally advanced, recurrent or metastatic, nonsquamous NSCLC [19]. 
In another front line Phase III study, bevacizumab was assessed in combination with cisplatin plus 
gemcitabine [20]. The study explored bevacizumab at two different dose levels, 7.5 and 15 mg/kg, 
showing a statistically significant improvement in PFS, the primary end point of the study, in both 
bevacizumab arms when compared with chemotherapy alone. The ORR was also significantly 
greater in both bevacizumab arms (37.8 and 30.6%, respectively, vs 21.6%). All treatment groups 
achieved a median OS greater than 13 months, but no difference in median OS was observed among 
treatment groups [21]. 
A systematic review and meta-analysis of four trials assessing the efficacy of chemotherapy plus 
bevacizumab versus chemotherapy alone in NSCLC included 2200 patients and confirmed a 
significantly higher ORR and a better PFS for bevacizumab treated patients with both 7.5 and 15 
mg/kg, while there was no statistically significant increase in OS [22]. The discrepancy between a 
clear benefit in PFS and a not consistent benefit in OS in the above mentioned studies may be the 
consequence of a different impact of postprogression therapies. 
In the USA, bevacizumab is currently licensed at dose of 15 mg/kg in combination with carboplatin 
plus paclitaxel as first-line therapy in patients with advanced nonsquamous NSCLC, while in 
Europe its use is in combination with platinum-based chemotherapy at the dose of both 7.5 or 15 
mg/kg. 
SaiL was a large Phase IV trial undertaken in a real-world population in order to assess the safety 
and efficacy of first-line bevacizumab combined with several standard chemotherapy regimens [23]. 
The study confirmed the manageable and consistent safety profile of bevacizumab, as well as its 
efficacy on treatment outcomes. Safety data coming from different studies excluded an excess of 
the risk of bleeding following bevacizumab use in NSCLC patients with CNS metastases [24,25] 
and led to the approval by EMA of bevacizumab in combination with a platinum-based 
chemotherapy even in patients with untreated CNS metastases [26]. 
A multicenter Phase II study evaluated the safety and efficacy of bevacizumab and pemetrexed 
maintenance after initial therapy with pemetrexed and carboplatin plus bevacizumab [27]. The 
study showed an ORR of 55% (95% CI: 41–69%) with a favorable toxicity profile. The median PFS 
and OS were 7.8 and 14.1 months, respectively. These promising results led to a subsequent Phase 
III comparison against the standard regimen containing bevacizumab. The PointBreak study was a 
multicenter, randomized Phase III study of pemetrexed/carboplatin plus bevacizumab as induction 
treatment followed by maintenance pemetrexed and bevacizumab compared with 
paclitaxel/carboplatin plus bevacizumab followed by bevacizumab maintenance in patients with 
advanced nonsquamous NSCLC [28]. The primary end point of superior OS for the pemetrexed 
containing arm was not met (12.6 vs 13.4 months; HR: 1.00; p = 0.949); however, the study showed 
a modest improvement in PFS for the pemetrexed arm (6.0 vs 5.6 months; HR: 0.83; p = 0.012) and 
a good safety profile [29]. 
Another study (AVAPERL1) investigated the efficacy of bevacizumab versus bevacizumab plus 
pemetrexed as maintenance treatment in nonsquamous patients who achieved disease control 
following induction with cisplatin and pemetrexed plus bevacizumab. The median PFS was 
significantly improved with the doublet (10.2 vs 6.6 months; HR: 0.50; p < 0.001) but this benefit 
was associated with significant increase of grade 3 and 4 toxicities in the combination maintenance 
arm [30]. 
• Reversible & irreversible EGF receptor–tyrosine kinase inhibitors  
Activation of the EGF receptor (EGFR) pathway promotes tumor growth and progression, 
stimulates cancer cell proliferation, invasion and metastasis, and inhibits apoptosis [31]. Although 
the therapeutic inhibition of this pathway have been pursued for more than 20 years only recently, 
following the detection of EGFR-sensitizing mutation in the EGFR gene tyrosine kinase domain, 
this pathway re-emerged as an attractive target for novel targeted strategies for NSCLC. 
Table 2 summarizes the initial series of Phase III trials evaluating the efficacy of oral EGFR–
tyrosine kinase inhibitors (TKIs; gefitinib and erlotinib) in combination with platinum-based 
chemotherapy in the first-line setting [32–35]. None of these studies demonstrated any statistically 
significant difference in OS between arms. Despite negative results, all these trials detected efficacy 
of the EGFR–TKIs associated with clinical characteristics as never smoking status, Asian ethnicity, 
female sex and adenocarcinoma histology [36,37]. 
The clinical development of gefitinib faced several hurdles. Although in 2003, single-agent gefitinib 
received accelerated approval by the FDA on the basis of encouraging Phase II data, the conditional 
approval was subsequently restricted in 2004 because of the negative results of the Phase III ISEL 
trial [38]. 
INTEREST was a large Phase III study that compared second-line gefitinib to docetaxel in 
unselected patients with adenocarcinoma of the lung and it demonstrated the noninferiority of 
gefitinib in comparison with docetaxel (HR: 1.02; 95% CI: 0.90–1.15). Patients treated with 
gefitinib had a lower rate of treatment-related toxicity (8.5 vs 40.7%) and a better improvement in 
quality of life and, once more, this study confirmed the superior activity of gefitinib in specific 
subgroups of patients with NSCLC [39]. 
In 2004, somatic gene mutations of the EGFR gene were discovered and their presence related to 
the higher response to EGFR–TKIs [40–42]. The most common mutations are in frame deletion in 
exon 19 around codons 746–750 (45–50% of all somatic EGFR mutations) and a missense mutation 
at codon 858 (L858R) in exon 21 (35–45% of all EGFR mutations). The frequency of mutations is 
ethnicity-related and more frequent in never smokers, women and patients with adenocarcinoma 
[43]. This discovery led to a new wave of studies that explored the role of gefitinib and other 
EGFR–TKIs in clinically enriched or molecularly defined patient populations (Table 3). 
First, IPASS provided evidence of efficacy of an EGFR–TKI inhibitor as front-line treatment in a 
clinically enriched population [44]. The study, designed to demonstrate the noninferiority of 
gefitinib versus chemotherapy in terms of PFS, met its primary end point and also showed the 
superiority of gefitinib versus chemotherapy in terms of PFS in the intention-to-treat analysis (HR: 
0.74; 95% CI: 0.65–0.85; p < 0.0001). Patients with tumor samples available for molecular analysis 
were considered in a subgroup analysis, which showed the superiority of gefitinib in terms of PFS 
in patients with EGFR-mutated tumors (HR: 0.48; 95% CI: 0.36–0.64; p < 0.0001). On the contrary, 
chemotherapy was significantly better in EGFR wild-type patients (HR: 2.85; 95% CI: 2.05–3.98; p 
< 0.0001) [44]. Final OS data, based on 78% of events, showed no differences between gefitinib 
and chemotherapy in the whole population (18.6 vs 17.3 months, respectively, HR: 0.91; 95% CI: 
0.76–1.10; p = 0.11) and in the mutation positive subgroup (HR: 1.00: 95% CI: 0.76–1.33). The 
improvement in PFS in gefitinib treated patients was coupled with a significant improvement in 
quality of life and a lower incidence of grade 3–4 adverse events compared with chemotherapy [50]. 
A similar study, the First-SIGNAL trial, compared gefitinib versus cisplatin plus gemcitabine in 
Korean patients [45]. While OS and PFS were similar in both groups (Table 3), the shape of the 
PFS curves resembled that seen in IPASS. Again in the EGFR mutation-positive patients, median 
PFS was significantly improved in the gefitinib arm (8.4 vs 6.7 months) as well as ORR (84.6 vs 
37.5%; p = 0.002). 
A series of other Phase III studies were conducted in genotype-defined EGFR mutant population 
which compared single-agent EGFR–TKI with cytotoxic chemotherapy and all invariably showed 
the superiority in terms of ORR and PFS of single-agent EGFR–TKI (Table 3) [46–49]. 
In July 2009, gefitinib received from EMA the approval for the treatment of locally advanced or 
metastatic NSCLC with activating mutations of the EGFR gene across all lines of therapy and, 
currently, is the treatment of choice for patients with advanced NSCLC harboring EGFR mutations. 
Among the above mentioned studies, mostly conducted among Asiatic patients, the EURTAC trial 
was the first performed in a Caucasian population and it proved the superiority of erlotinib versus 
chemotherapy as front-line treatment [49]. Median PFS was 9.7 months (95% CI: 8.4–12.3) for 
patients treated with erlotinib compared with 5.2 months (95% CI: 4.5–5.8) for those treated with 
standard chemotherapy. 
Sequential use of chemotherapy and EGFR TKIs has been tested as an alternative strategy in the 
first-line setting. FAST-ACT was a Phase II study that investigated whether the sequential 
administration of erlotinib and chemotherapy versus chemotherapy alone improves clinical 
outcomes in unselected, previously untreated patients with advanced NSCLC [51]. Patients were 
randomly assigned to receive erlotinib or placebo on days 15–28 of a 4-week cycle that included 
cisplatin or carboplatin plus gemcitabine. The primary end point of the study was non-progression 
rate (NPR) at 8 weeks. No significant difference in NPR was observed between the two treatment 
arms (80.3 vs 76.9%, in the erlotinib and placebo arm respectively; p = 0.51). ORR was higher in 
the chemotherapy-erlotinib arm (35.5 vs 24.4%, respectively) and median PFS was also 
significantly longer in the erlotinib arm (29.4 vs 23.4 weeks, in the erlotinib and placebo arm 
respectively; HR: 0.47; 95% CI: 0.33–0.68; p = 0.0002) No significant difference in OS was 
observed [51]. These encouraging results led to a large confirmatory randomized Phase III trial, the 
FAST-ACT II trial, which showed a significantly prolonged PFS with erlotinib versus placebo (7.6 
vs 6.0 months, respectively; HR: 0.57; 95% CI: 0.46–0.70; p < 0.0001). ORR was significantly 
improved in the erlotinib arm (42.9 vs 17.8%, respectively; p < 0.0001) and a nonsignificant trend 
toward longer OS was seen with erlotinib versus placebo (18.3 vs 14.9 months, respectively; HR: 
0.78; 95% CI: 0.60–1.02; p = 0.069) [52]. 
Another interesting therapeutic challenge for physicians is how best to manage at the best patients 
who benefited from EGFR-TKIs, but then experienced disease progression after a durable response. 
Several cases report and retrospective analyses indicated that responsive patients to EGFR–TKIs 
were successfully under therapeutic control after subsequent re-administration of the same EGFR–
TKIs or another agent with a similar mechanism of action, supporting the hypothesis that these 
EGFR-mutated tumors continue to be 'oncogene-addicted' to EGFR [53–55]. Prospective trials have 
recently showed that the re-administration of EFGR–TKIs in those patients who initially responded 
to these agents and then were treated at progression with systemic chemotherapy could be a valid 
therapeutic option at the time of second progression albeit with a lower ORR and PFS [56,57]. 
Acquired resistance to EGFR–TKIs is most commonly characterized by the presence of the 
gatekeeper mutation T790M [58,59]. Among second-generation TKIs afatinib (BIBW2992) is an 
irreversible ErbB-family blocker with potent activity against NSCLCs harboring activating EGFR 
mutations and/or the gatekeeper mutation T790M, albeit at lower potency. It has been recently 
evaluated in several clinical trials for advanced NSCLC with promising results (Table 4) [60–63]. 
The LUX-Lung 3 was a front-line Phase III trial of afatinib versus cisplatin/pemetrexed for patients 
with advanced lung adenocarcinoma harboring EGFR-activating mutations. Patients treated with 
afatinib had a median PFS, the primary end point of the study, of 11.1 versus 6.9 months for the 
chemotherapy group (HR: 0.58; 95% CI: 0.43–0.78; p = 0.0004). ORR was also significantly higher 
with afatinib (56 vs 23%; p < 0.001), reporting a consistent delay in time to deterioration of cancer-
related symptoms [62]. Most common afatinib-related adverse events were diarrhea (95%), skin 
rash (62%) and paronychia (57%). On the basis of results coming from the LUX-Lung 3 trial, 
afatinib has been recently approved by the FDA and by EMA for the first-line treatment of EGFR 
mutation-positive metastatic NSCLC. 
Another study, LUX-Lung 6 compared afatinib with cisplatin plus gemcitabine in Asiatic patients 
with EGFR mutation-positive advanced adenocarcinoma of the lung (Table 4). The study showed a 
clear benefit in terms of median PFS (11.0 vs 5.6 months; HR: 0.28; 95% CI: 0.20–0.39; p < 
0.0001) and ORR (66.9 vs 23.0%; p < 0.0001) in favor of afatinib, which showed a favorable 
tolerability profile, with few cases of grade 3 and 4 toxicities [63]. Currently, afatinib is currently 
under evaluation in a Phase II trial against gefitinib as first-line treatment in advanced NSCLC 
patients with EGFR-activating mutations [64]. 
Another second-generation TKI, dacomitinib (PF-00299804) – an irreversible inhibitor of 
EGFR/HER1, HER2 and HER4, has been evaluated in a Phase II trial versus erlotinib in previously 
treated (one/two prior chemotherapy regimens were allowed) advanced NSCLC patients. The 
median PFS was 2.86 months for patients treated with dacomitinib and 1.91 months for those 
treated with erlotinib (HR: 0.66; 95% CI: 0.47–0.91; p = 0.012), while median OS was 9.53 and 
7.44 months, respectively (HR: 0.80; 95% CI: 0.56–1.13; p = 0.205). The most common treatment-
related adverse events were dermatologic and gastrointestinal disorders, mostly of grade 1 and 2, 
and more frequently associated with dacomitinib [65]. These results represented the backbone 
information for an ongoing Phase III study in which 800 patients will be enrolled having as primary 
end point PFS [66]. 
• Monoclonal antibodies anti-EGFR: cetuximab  
Cetuximab is a chimeric monoclonal antibody that selectively binds the extracellular domain of the 
EGFR on the tumor cell and inhibits the receptor-associated tyrosine kinase activation [67,68]. A 
large Phase III trial (FLEX) compared cisplatin plus vinorelbine with the same combination plus 
cetuximab in chemotherapy-naive advanced NSCLC patients with EGFR-positive tumors (≥1% 
positive cells) as assessed by immunohistochemistry [69]. The addition of cetuximab demonstrated 
a small but statistically significant benefit in terms of median OS over chemotherapy alone (11.3 vs 
10.1 months, respectively, HR 0.87; p = 0.0441), while PFS was similar in both arms. The main 
cetuximab-associated toxicity was acne-like rush, which occurred in 10% of patients. Similar results 
were observed in another trial with a different chemotherapy backbone [70]. This second study did 
not show improvement of PFS, but showed a trend to improved OS, the secondary end point of the 
study, for patients treated with cetuximab plus chemotherapy (9.7 vs 8.4 months, respectively, HR: 
0.890; 95% CI: 0.75–1.05; p = 0.17). 
A meta-analysis considered four cetuximab studies and included 1003 and 1015 patients treated 
with chemotherapy plus cetuximab or chemotherapy alone, respectively [71]; it showed a 9% 
reduction in the risk of disease progression (HR: 0.91; 95% CI: 0.83–1.00; p = 0.06), a 13% 
reduction in the risk of death (HR: 0.87; 95% CI: 0.78–0.96; p = 0.005) and an approximately 50% 
increase in ORR (odds ratio: 1.48; 95% CI: 1.22–1.80; p < 0.0001) for cetuximab-treated patients 
[71]. 
High levels of EGFR expression correlate with in vitro sensitivity to cetuximab [72,73]. Recently, 
FLEX data were reanalyzed and the immunohistochemistry assessment of EGFR intensity and 
frequency in tumor cells was used to generate, on a continuous scale of 0–300, an EGFR 
immunohistochemistry (EGFR IHC) score for each assessable patient, in order to investigate 
whether tumor EGFR expression levels were associated with a predictive role. Treatment outcomes 
were analyzed in patients with a low (<200) and high (≥200) EGFR IHC score, representing 69 and 
31% of evaluable patients, respectively [74]. For patients with a high EGFR IHC score, median OS 
was longer in the chemotherapy plus cetuximab arm than in the control arm (12.0 vs 9.6 months, 
respectively; HR: 0.73, 95% CI: 0.58–0.93; p = 0.011), without significant increase in cetuximab 
related side effects. No corresponding survival benefit was observed in the group of patients with 
low EGFR IHC score (median OS of 9.8 vs 10.3 months, respectively; HR: 0.99; 95% CI: 0.84–
1.16; p = 0.88) [74]. 
A fully humanized monoclonal antibody targeting the EGFR extracellular domain III, 
necitumumab, is currently under investigation having the potential benefit of lower hypersensitivity 
reaction risk as compared with cetuximab and also equivalent antibody-dependent cell-mediated 
cytotoxicity [75]. The Phase III trial INSPIRE (NCT00982111) that evaluated the addition of 
necitumumab to cisplatin/pemetrexed as first-line treatment for advanced nonsquamous NSCLC 
was prematurely closed owing to the increased risk of thromboembolic events in the experimental 
arm [76]. The SQUIRE trial (NCT00981058) is another Phase III study of first-line 
cisplatin/gemcitabine plus necitumumab versus chemotherapy alone for advanced squamous 
NSCLC [77]. The study fully accrued the requested number of patients and a recent press release 
indicated that it met its primary end point. 
• ALK inhibitors  
ALK is one of the newest and attractive biological targets in NSCLC. ALK is aberrantly activated 
because of a chromosomal rearrangement in approximately 4% of NSCLC tumors, leading to the 
expression of an oncogenic fusion protein, such as EML4–ALK [78,79]. In NSCLC, the ALK gene 
rearrangement is associated with specific clinical–pathological features, including male sex, young 
age, absent or minimal smoking history, adenocarcinoma histology and usually mutual exclusivity 
between EML4–ALK and EGFR and KRAS mutations [80–82]. Preclinical and clinical studies have 
shown that cancer cells harboring EML4–ALK and other ALK abnormalities are exquisitely 
sensitive to ALK inhibition [79,83]. 
The identification of EML4–ALK as an oncogenic driver in NSCLC occurred relatively early in the 
clinical development of crizotinib, an ALK inhibitor originally under investigation as a c-MET 
inhibitor, and led to the rapid clinical development of this drug [84]. Initial results from the Phase I 
study clearly indicated significant and clinically relevant tumor shrinkage in the majority of 
enrolled patients [85]. Subsequently, an expansion cohort of 82 NSCLC patients harboring the ALK 
rearrangement was enrolled at the recommended dose of 250 mg twice daily. The ORR for the 
expanded cohort was 57% (46 partial responses and one complete response). An additional 33% of 
patients had stable disease at the 8-week assessment [86]. An update of this study with 119 enrolled 
patients was subsequently presented showing a consistent ORR of 61% with two complete 
responses and 69 partial responses and the median PFS for was 10 months (95% CI: 8.00–15.00) 
[87]. Based upon the encouraging ORR of the Phase I study, a large multicenter second- and 
subsequent-line study in ALK-positive NSCLC patients was initiated. Patient characteristics largely 
corresponded to those of the previous study and the ORR was 51% [88]. In both the Phase I and II 
trials, the majority of responses was achieved during the first 8 weeks of treatment and duration of 
response was 48.1 and 41.9 weeks, respectively [87,88]. 
In August 2011, based on the Phase I and II trial data, the FDA granted in USA accelerated 
approval of crizotinib for the first or subsequent lines of treatment of locally advanced or metastatic 
ALK-positive NSCLC [89]. Final FDA approval will be contingent on analysis of outcome 
measures in the ongoing Phase III studies [90,91]. 
PROFILE 1007, a Phase III study evaluating the use of crizotinib versus pemetrexed or docetaxel as 
second line of treatment for ALK-positive NSCLC patients met its primary end point by 
demonstrating the superiority of crizotinib over chemotherapy in prolonging PFS (7.7 vs 3.0 
months, respectively; HR: 0.49) and ORR (65 vs 20%; p < 0.0001), while the safety profile was 
acceptable [92]. These findings led to the EMA authorization for the use of crizotinib as the 
standard of care for previously treated ALK-positive NSCLC patients in Europe. 
As already reported above, the TS level may predict the sensitivity to pemetrexed-based 
chemotherapy in different histologic subtypes of NSCLC, being inversely correlated with 
pemetrexed efficacy [16]. A recent study evaluating the role of pemetrexed-based chemotherapy in 
ALK-positive NSCLC patients, showed lower TS levels than the median values established in 
unselected cases. A low TS level has been observed in almost 83% of the evaluated patients (p = 
0.039) and the few ALK-positive NSCLC patients with high TS levels had the poorest survival 
outcomes observed [93]. These findings suggest that differences in TS expression levels in ALK-
positive NSCLC patients may predict the differential responses to pemetrexed, but also justify the 
superior efficacy of pemetrexed compared with docetaxel in this subset of patients, as observed in 
the PROFILE 1007. 
Another Phase III trial PROFILE 1014 (NCT01154140) is currently actively recruiting patients to 
evaluate the efficacy and safety of crizotinib versus cisplatin or carboplatin/pemetrexed as a first-
line treatment for previously untreated ALK-positive nons1quamous NSCLC patients [91]. The 
primary end point of the study is PFS, while ORR and OS are included among the secondary end 
points. A superiority Phase III trial testing the same crizotinib schedule has been designed for the 
east Asian population [94]. 
Crizotinib has recently also demonstrated a marked anti-tumor activity in patients with advanced 
NSCLC harboring ROS1 chromosomal rearrangements, which leads to the expression of oncogenic 
ROS1 fusion kinases and to sensitivity to ROS kinase inhibition, without any overlap with other 
oncogenic drivers. This rearrangement has been detected in almost 1% of NSCLC cases, usually in 
younger patients, never or light smokers and with adenocarcinoma histology [95,96]. 
The expansion cohort of the Phase I study of crizotinib PROFILE 1001 (NCT00585195) recruited 
patients with advanced NSCLC harboring ROS1 rearrangement, as determined using a break-apart 
FISH assay [97]. The study showed an ORR of 54% and a disease control rate at 8 weeks of 85%, 
with a safety profile similar to that observed in ALK-positive NSCLC patients receiving crizotinib 
[97]. 
Conclusion & future perspective 
 
Moving toward the next decade and looking to the several landmark changes in the understanding 
the biology and treatment of NSCLC that we observed in the last few years, it is almost impossible 
to deny that significant improvements have been made in extending survival of selected groups of 
patients with tumors harboring specific genomic alterations. Although such genetic changes have 
been detected in more than 50% of adenocarcinoma and, more recently also, in the vast majority of 
squamous cell carcinoma and small cell lung cancers, effective and approved targeted therapy 
approaches are currently available only for a significant minority of our patients. EGFR–TKIs 
should be the preferred front-line treatment choice for advanced patients with nonsquamous tumors 
harboring EGFR-sensitizing mutations. For patients harboring ALK gene rearrangements an 
attractive and promising strategy of treatment is represented by crizotinib and second-generation 
ALK-inhibiting agents. Up to date, despite the huge effort of clinical research therapeutic choices 
based on histology are still the standard of care for the majority of patients with advanced NSCLC. 
In the setting of nononcogene addicted nonsquamous NSCLC patients, either the combination of a 
platinum agent with pemetrexed or the addition of bevacizumab to carboplatin and paclitaxel are 
doable therapeutic solutions and the choice should be guided by clinical, pathologic and cost-
efficacy issues. In squamous histology, doublet platinum-based chemotherapy remains the standard 
approach. 
Although the implementation of the systematic sequencing of the lung cancer genome will 
definitively lead to a progressive increase of the proportion of patients that will be treated by 
specific targeted therapies, it is quite unlikely that a druggable target or more than one target will be 
discovered and efficiently blocked in every tumor. More potential crosstalks exist between cancer 
pathways, allowing new DNA mutations to create new pathways to cancer when pre-existing ones 
are blocked. Given the seemingly almost intrinsic genetic instability of many late-stage cancers we 
should question if we will be able to truly cure most victims of widespread metastatic cancer. 
In addition, tumors exposed to effective targeted therapies develop, sooner or later, acquired 
resistance and it can be hypothesized that resistance to gene-targeted agents also comes as a 
consequence of the radical changes in the underlying patterns of gene expression that accompany 
the epithelial–mesenchymal cell transitions in cancer cells when their surrounding environments 
become hypoxic. 
It should additionally be noted that areas of further exploration are focusing on the inhibition of the 
complex DNA repair machinery and, more specifically, on homologous recombination and end 
joining mechanisms to repair double strand breaks which arise from ionizing radiation or x-rays, 
free radicals and chemicals including cytotoxics. 
In the near future, we will focus much more on the wide range of metabolic and oxidative 
vulnerabilities that arise as consequences of the uncontrolled growth and proliferation capacities of 
cancer cells. 
Only the definition of homogeneous subgroups of tumors with the same genetic and metabolic 
characteristics and the search for individualized approaches could represent the way to improve 
survival expectancy for these patients. 
Table 1.  Therapeutic plateau of platinum-based chemotherapy involving third-generation 
agents as first-line treatment for non-small-cell lung cancer. 
 
Table 2.  Phase III randomized studies comparing tyrosine kinase inhibitors with platinum-
based chemotherapy as first-line treatment in 'unselected' non-small-cell lung cancer. 
 Table 3.  Phase III randomized studies comparing tyrosine kinase inhibitors with platinum-
based chemotherapy as first-line treatment in 'selected' non-small-cell lung cancer. 
 
 
Table 4.  Relevant clinical trials of afatinib for advanced non-small-cell lung cancer. 
 
EXECUTIVE SUMMARY 
 
Background  
Lung cancer is the leading cause of cancer-related mortality worldwide, and the actual challenge 
is to better personalize the therapeutic approaches to improve survival expectancy. 
Role of standard chemotherapy  
Platinum-based chemotherapy doublets are the backbone of treatment for non-small-cell lung 
cancer (NSCLC), giving a modest but significant improvement in survival and quality of life in 
comparison with best supportive care. 
Cisplatin is more effective than carboplatin in terms of objective response rate (ORR) and 
overall survival (OS). 
Triplet combinations are associated with increased ORR but similar survival. 
Histology-driven chemotherapy  
On the basis of survival benefit, pemetrexed in combination with cisplatin has been granted as 
first-line treatment for advanced nonsquamous NSCLC. 
Role of biological agents  
Bevacizumab, a monoclonal antibody anti-VEGFR, has been licensed in the USA in 
combination with carboplatin/paclitaxel as first-line treatment option for advanced 
nonsquamous NSCLC, on the basis of its survival benefit; in Europe it is licensed in 
combination with any platinum-based chemotherapy. 
 In NSCLC patients with EGFR mutation-positive tumors, first-line single-agent therapy 
with either gefitinib or erlotinib, two reversible EGFR–TKIs, when compared with standard 
platinum-based chemotherapy, are associated with a significantly longer PFS, higher ORR, a 
more favorable toxicity profile and better quality of life. 
 Gefitinib and erlotinib received from EMA, the authorization for the treatment of locally 
advanced or metastatic EGFR mutation-positive NSCLC, across all lines of therapy. 
 Afatinib, an irreversible EGFR–TKI, has recently showed a clear survival benefit in terms of 
PFS in NSCLC patients harboring EGFR-activating mutations, receiving from the US FDA 
and the EMA the authorization for first-line treatment in this subgroup of patients. 
 Cetuximab, a monoclonal antibody anti-EGFR, in association with platinum-based 
chemotherapy has demonstrated a small but significant survival benefit in terms of OS, 
despite a more severe toxicity profile. 
 Crizotinib, an ALK inhibitor, has showed significant and clinically relevant tumor shrinkage 
in the majority of ALK-positive NSCLC patients. 
 In the USA, it has been licensed for the treatment of locally advanced or metastatic ALK-
positive NSCLCs across all lines of therapy, while in Europe its use is allowed in previously 
treated NSCLC patients harboring ALK gene rearrangements. 
 Crizotinib has recently demonstrated a marked anti-tumor activity in NSCLC patients 
harboring ROS1 chromosomal rearrangements. 
Conclusion & future perspective  
 The definition of homogeneous subgroups of tumors with the same genetic characteristics 
and the search for individualized approaches could improve survival expectancy for NSCLC 
patients. 
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